"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT00419081","Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens",,"Terminated","No Results Available","Leukemia|Lymphoma","Drug: Forodesine Hydrochloride Sterile Solution, 5 mg/mL|Drug: Forodesine Hydrochloride Capsules (100 mg)","To determine the rate of complete remission for T lymphoblastic leukemia/lymphoma relapsed or refractory patients. The complete remission rate will be evaluated over the three-month Initial Treatment Period.|To determine the rate of CR achieved based on prior HSCT status|Assess safety and tolerability|Assess survival end points|Evaluate the maintenance and duration of response|Evaluate the proportion of patients able to proceed to HSCT|Evaluate the effects of this forodesine regimen on plasma levels of dGuo|Determine the effects of this forodesine regimen on clinical end points|Explore potential predictive biomarkers","BioCryst Pharmaceuticals","All","18 Years and older Â  (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCX1777-Tio-05-202","July 2006","March 2007","March 2007","January 8, 2007","null","January 23, 2012","University of Chicago Medical Center, Chicago, Illinois, United States|Louisana State University Health Sciences Center, Shreveport, Louisiana, United States|New York Medical College Division of Oncology, Valhalla, New York, United States|Liberty Hematology and Oncology, Columbia, South Carolina, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00419081"
